Biomatlante’s MBCP Matrix Selected for Fracture Study

By Julie A. Vetalice

MBCP+™, Biomatlante's synthetic bone graft matrix, has been confirmed as the adapted matrix of choice for tissue engineering and was selected for use in a 5-year trial in the treatment of long bone nonunions.

The ORTHOUNION randomized clinical trial will compare a combination of MBCP+ and expanded bone marrow mesenchymal stem cells (MSCs) to autograft in the treatment of long bone nonunions. ORTHOUNION is funded with €6MM from the EU's Horizon 2020 research and innovation program.

This follows 2016 results of the REBORNE study, which demonstrated a high rate of clinical success from a combination of MBCP+ and MSCs, particularly in the treatment of long bone nonunions. MBCP+ will also be used in a trial focusing on use prior to dental surgery.

Sources: Biomatlante; ec.europa.eu; ORTHOWORLD Inc.

Product Labels: Synthetic Bone Graft

Tags: Trial/Study